What does Milestone Pharmaceuticals, Inc. do?

Jun 22 2025 06:18 PM IST
share
Share Via
Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing etripamil for cardiovascular treatments. As of March 2025, it has a market cap of $92.49 million and reported a net profit loss of $21 million.
Overview:
Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing etripamil for the treatment of cardiovascular indications within the Pharmaceuticals & Biotechnology industry.

Financial Snapshot:
Most recent Net Profit: -21 Million (Quarterly Results - Mar 2025)
Market cap: USD 92.49 Million (Micro Cap)

Key Metrics:
P/E: NA (Loss Making)
Industry P/E: NA
Dividend Yield: 0.00%
Debt Equity: 0.18
Return on Equity: 848.05%
Price to Book: -15.11

Contact Details:
Address: 1111 Dr.-Frederik-Philips Blvd Suite 420, SAINT-LAURENT QC: H4M 2X6
Tel: 1 514 3360444
Website: https://www.milestonepharma.com
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News